Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

2.386 +0.136 (+6.07%)
Streaming Delayed Price Updated: 1:57 PM EDT, Aug 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ImmunityBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock
From ImmunityBio, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Top 2 Health Care Stocks That May Fall Off A Cliff This Month
 
Via Benzinga
ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Reports Third-Quarter 2024 Financial Results
From ImmunityBio, Inc.
Via Business Wire
IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Trump Media & Tech, ImmunityBio, And iRhythm Are Among Top 10 Mid Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?
These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio? 
Via Benzinga
Topics Government
Jeff Bezos Ends Washington Post's 36-Year Tradition Of Endorsements, Leaving Staff 'Roiled'
The Washington Post is not endorsing a candidate in a presidential election for the first time since 1988. Sources say the decision came from Jeff Bezos. 
Via Benzinga
Booz Allen Posts Upbeat Q3 Earnings, Joins Deckers Outdoor, Saia, Boyd Gaming And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma
From ImmunityBio, Inc.
Via Business Wire
800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio
EF Hutton rates ImmunityBio (IBRX) as a Buy with a $30 target. Anktiva shows promise in cancer treatment, boosting response rates and survival outcomes. 
Via Benzinga
Texas Instruments Posts Strong Q3 Results, Joins Valmont Industries, Lithia Motors, Teledyne Technologies And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
ImmunityBio to Participate in the Jefferies London Healthcare Conference
From ImmunityBio, Inc.
Via Business Wire
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer
From ImmunityBio, Inc.
Via Business Wire
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
 
Via Benzinga
Top 3 Health Care Stocks That Are Set To Fly This Quarter
 
Via Benzinga
9 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
IBRX Stock Earnings: ImmunityBio Misses EPS, Misses Revenue for Q2 2024
IBRX stock results show that ImmunityBio missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer
From ImmunityBio, Inc.
Via Business Wire
IMMUNITYBIO INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ImmunityBio, Inc. - IBRX
From Kahn Swick & Foti, LLC
Via Business Wire
7 Biotech Stocks to Keep on Your Clinical Radar
Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs. 
Via InvestorPlace
3 Top Cancer Treatment Stocks to Buy Now
These cancer treatment stocks are well-positioned to benefit tremendously from strong demand for their cancer treatments in the longer term. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.